mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus
Status:
Unknown status
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some
showed that irinotecan may be effective. The investigators previous study has shown the
efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study,
the investigators would like to observe the efficacy and safety of Nimotuzumab plus
Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of
PTX/DDP.